玻璃体腔内注射雷珠单抗联合532nm激光光凝治疗缺血型视网膜静脉阻塞患者的疗效观察  

Observation of Carative Effect of Intravitreal Injection of Ranibizumab Combined with 532nm Laser Photocoagulation in Patients with Ischemic Retinal Vein Occlusion

作　　者：陆骏 秦瑜 肖文玮 刘芳 LU Jun;QIN Yu;XIAO Wenwei(Shanghai Integrated Traditional Chinese and Western Medicine Hospital Affiliated toShanghai University of Traditional Chinese Medicine, Shanghai 200082, China)

机构地区：[1]上海中医药大学附属上海市中西医结合医院眼科

出　　处：《河北医学》2019年第5期732-737,共6页Hebei Medicine

基　　金：上海市自然科学基金项目,(编号:15ZR1434312)

摘　　要：目的:观察玻璃体腔内注射雷珠单抗联合532nm激光光凝治疗缺血型视网膜静脉阻塞(RVO)患者的短期疗效。方法:选取2015年10月至2017年10月我院缺血型RVO患者78例(78眼),依据简单随机分组法分为试验组39例(39眼)与对照组39例(39眼)。对照组予以532nm激光光凝治疗,试验组采取玻璃体腔内注射雷珠单抗联合532nm激光光凝治疗。治疗后进行6个月随访,比较两组临床效果、视网膜渗漏情况与治疗前、治疗后1个月、3个月、6个月最佳矫正视力(BCVA)、黄斑中心视网膜厚度(CMT)、生活质量评分(SF-36)。结果:治疗后6个月试验组总有效率94.87%较对照组76.92%高,差异有统计学意义(P<0.05);治疗后6个月试验组视网膜渗漏程度较对照组低,差异有统计学意义(P<0.05);治疗后1个月、3个月、6个月两组BCVA、SF-36评分均呈增高趋势,且试验组增高幅度较大,两组BCVA组间、不同时间点及组间·不同时间点交互作用相比,差异有统计学意义(P<0.05);治疗后1个月、3个月、6个月两组CMT呈降低趋势,且试验组降低幅度较大,两组CMT组间、不同时间点及组间·不同时间点交互作用相比,差异有统计学意义(P<0.05)。结论:缺血型视网膜静脉阻塞患者联合应用玻璃体腔内注射雷珠单抗与532nm激光光凝治疗可提升临床效果,提高视力,减轻视网膜渗漏及黄斑水肿,改善患者生活质量,近期疗效确切。Objective: To observe the short-term efficacy of intravitreal injection of ranibizumab combined with 532nm laser photocoagulation in patients with ischemic retinal vein occlusion (RVO). Methods: From October 2015 to October 2017, 78 patients (78 eyes) with ischemic RVO were enrolled. According to the random number table, 39 patients (39 eyes) and 39 patients (39 eyes) were included in the control group. The control group was treated with 532 nm laser photocoagulation. The experimental group was treated with intravitreal injection of ranibizumab plus 532 nm laser photocoagulation. Six-month follow-up after treatment was proceeded;the clinical effects, quality of life score (SF-36) retinal leakage and best corrected visual acuity (BCVA), macular central retinal thickness (CMT) during pre-treatment, 1 month, 3 months, 6 months after treatment were compared. Results: The total effective rate of the test group was 94.87% higher than that of the control group at 6 months after treatment, and the difference was statistically significant (P<0.05). The degree of retinal leakage in the test group was lower than that of the control group at 6 months after treatment. The difference was statistically significant. Significance (P<0.05);BCVA and SF-36 scores increased at 1 month, 3 months, and 6 months after treatment, and the test group increased significantly. The BCVA group and the different time points in the two groups. Compared with the interaction between groups and at different time points, the difference was statistically significant (P<0.05). The CMT of the two groups decreased at 1 month, 3 months and 6 months after treatment, and the test group decreased greatly. There was statistically significant difference between the two groups of CMT groups, at different time points, and between groups at different time points (P<0.05). Conclusion: Patients with ischemic retinal vein occlusion combined with intravitreal injection of ranibizumab and 532nm laser photocoagulation can improve clinical outcomes, improve visual acuit

关 键 词：缺血型视网膜静脉阻塞 雷珠单抗 532nm激光光凝 

分 类 号：R779.63[医药卫生—眼科]